Chong Kun Dang185750.KS

About Chong Kun Dang

Chong Kun Dang Pharmaceutical is one of Korea's leading prescription drugmakers, spun out as the operating company when the decades-old group adopted a holding structure under Chong Kun Dang Holdings. Its portfolio emphasizes domestically marketed prescription medicines, from cardiovascular and metabolic treatments to antibiotics, many of them co-promoted with multinational partners, alongside biosimilar biologics that include an anemia treatment sold in Japan. The company also pursues new-drug research and has out-licensed pipeline assets to global drugmakers. Revenue rests primarily on high-volume domestic prescriptions, supported by consumer health products and export sales.

The profile is more domestic than most Korean health-care names foreign investors encounter: earnings depend on prescription volumes inside Korea's national insurance system, making government reimbursement pricing the dominant structural sensitivity. Co-promotion agreements with multinational drugmakers provide dependable revenue but involve contract renewals that can swing the top line when partners change strategy. Licensing deals on research assets add optional upside with the lumpiness such payments imply. The holding-company layer above, under founding-family control, follows the standard Korean template, and the stock is generally owned for steady pharmaceutical exposure rather than pipeline speculation.

The Chong Kun Dang name dates to 1941, when founder Lee Chong-kun opened a small Seoul pharmacy that grew into one of Korea's pioneering drug manufacturers and an early builder of domestic antibiotic and raw-material production. Leadership passed to the founder's son, chairman Lee Jang-han. In November 2013 the decades-old corporation split itself into Chong Kun Dang Holdings and the present Chong Kun Dang Pharmaceutical, which inherited the drug business along with its own fresh stock listing. The operating company has since combined its traditional prescription franchise with biosimilar development and research out-licensing, including an agreement handing an early-stage candidate to Novartis in 2023.

Chong Kun Dang's engine is its prescription sales force, among the largest in Korea, which converts relationships with doctors and hospitals into high-volume prescriptions for its own medicines and for products co-promoted with multinational partners, who supply the drugs while CKD supplies the reach. Biosimilars add manufacturing-based export income, including an anemia biosimilar marketed in Japan through a local partner. Consumer health products extend the brand into pharmacies. Because most revenue is earned inside the national reimbursement system, government pricing rules set the ceiling, and the company competes with Yuhan, HK inno.N, and Daewoong for formulary presence, with out-licensing providing occasional windfalls.

Company profile by LineVest editorial. Journalism, not investment advice. Commission a full DART-based report on Chong Kun Dang →